JP2010043069A - Composition for improving bowel movement and skin - Google Patents
Composition for improving bowel movement and skin Download PDFInfo
- Publication number
- JP2010043069A JP2010043069A JP2009162741A JP2009162741A JP2010043069A JP 2010043069 A JP2010043069 A JP 2010043069A JP 2009162741 A JP2009162741 A JP 2009162741A JP 2009162741 A JP2009162741 A JP 2009162741A JP 2010043069 A JP2010043069 A JP 2010043069A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- improvement
- improving
- pearl barley
- acne
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 26
- 102000004190 Enzymes Human genes 0.000 claims abstract description 92
- 108090000790 Enzymes Proteins 0.000 claims abstract description 92
- 229940088598 enzyme Drugs 0.000 claims abstract description 92
- 206010000496 acne Diseases 0.000 claims abstract description 67
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 42
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 35
- 108091005804 Peptidases Proteins 0.000 claims abstract description 29
- 239000004365 Protease Substances 0.000 claims abstract description 26
- 208000008930 Low Back Pain Diseases 0.000 claims abstract description 23
- 230000008961 swelling Effects 0.000 claims abstract description 23
- 108090000637 alpha-Amylases Proteins 0.000 claims abstract description 21
- 102000004139 alpha-Amylases Human genes 0.000 claims abstract description 21
- 229940024171 alpha-amylase Drugs 0.000 claims abstract description 21
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 2
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 119
- 240000005979 Hordeum vulgare Species 0.000 claims description 118
- 230000006872 improvement Effects 0.000 claims description 80
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 66
- 239000007857 degradation product Substances 0.000 claims description 46
- 239000000047 product Substances 0.000 claims description 43
- 230000036541 health Effects 0.000 claims description 31
- 208000008035 Back Pain Diseases 0.000 claims description 23
- 210000003608 fece Anatomy 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 claims 1
- 102100034866 Kallikrein-6 Human genes 0.000 claims 1
- 241001565331 Margarodes Species 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 208000000260 Warts Diseases 0.000 abstract description 26
- 201000010153 skin papilloma Diseases 0.000 abstract description 26
- 239000010903 husk Substances 0.000 abstract description 2
- 235000007354 Coix lacryma jobi Nutrition 0.000 abstract 5
- 244000077995 Coix lacryma jobi Species 0.000 abstract 5
- 239000000463 material Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 62
- 239000000843 powder Substances 0.000 description 58
- 210000003491 skin Anatomy 0.000 description 47
- 230000000694 effects Effects 0.000 description 39
- 239000000284 extract Substances 0.000 description 35
- 102000035195 Peptidases Human genes 0.000 description 27
- 239000009538 yokuinin Substances 0.000 description 27
- 235000019419 proteases Nutrition 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000002775 capsule Substances 0.000 description 15
- 230000007515 enzymatic degradation Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 241000219051 Fagopyrum Species 0.000 description 12
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 11
- 235000013339 cereals Nutrition 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 102000013142 Amylases Human genes 0.000 description 9
- 108010065511 Amylases Proteins 0.000 description 9
- 239000004382 Amylase Substances 0.000 description 8
- 235000019418 amylase Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 6
- 230000013872 defecation Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002366 lipolytic effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000228212 Aspergillus Species 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000519695 Ilex integra Species 0.000 description 4
- 241000234295 Musa Species 0.000 description 4
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 108010059892 Cellulase Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 229940106157 cellulase Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108010021511 Aspergillus oryzae carboxyl proteinase Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 102100022624 Glucoamylase Human genes 0.000 description 2
- 102000004366 Glucosidases Human genes 0.000 description 2
- 108010056771 Glucosidases Proteins 0.000 description 2
- 102000051366 Glycosyltransferases Human genes 0.000 description 2
- 108700023372 Glycosyltransferases Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000035092 Neutral proteases Human genes 0.000 description 2
- 108091005507 Neutral proteases Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- 229920000294 Resistant starch Polymers 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003625 amylolytic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940069780 barley extract Drugs 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 108010019077 beta-Amylase Proteins 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000004464 cereal grain Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 108010093305 exopolygalacturonase Proteins 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940059442 hemicellulase Drugs 0.000 description 2
- 108010002430 hemicellulase Proteins 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 235000020007 pale lager Nutrition 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000021254 resistant starch Nutrition 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100033770 Alpha-amylase 1C Human genes 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- ZCLAHGAZPPEVDX-UHFFFAOYSA-N D-panose Natural products OC1C(O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC1COC1C(O)C(O)C(O)C(CO)O1 ZCLAHGAZPPEVDX-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 1
- 101000779870 Homo sapiens Alpha-amylase 1B Proteins 0.000 description 1
- 101000779869 Homo sapiens Alpha-amylase 1C Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 229940111205 diastase Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- FBJQEBRMDXPWNX-FYHZSNTMSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)C(O)O2)O)O1 FBJQEBRMDXPWNX-FYHZSNTMSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 description 1
- ZCLAHGAZPPEVDX-MQHGYYCBSA-N panose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZCLAHGAZPPEVDX-MQHGYYCBSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000037070 skin defense Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は殻付きハトムギの粉砕物を原料とするハトムギ酵素分解物、ハトムギ酵素分解物からなる便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善並びに皮膚改善剤及びハトムギ酵素分解物を含有する便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善並びに皮膚改善用組成物に関する。 The present invention relates to a pearl barley enzyme degradation product made from crushed shelled pearl barley, a bowel movement consisting of a pearl barley enzyme degradation product, low back pain, premenstrual syndrome (PMS), swelling, warts, and a skin improving agent and pearl barley enzyme degradation product. The present invention relates to a composition for improving bowel movements, low back pain, premenstrual syndrome (PMS), swelling, warts, and skin.
従来より、ハトムギを原料とし、皮膚の状態を改善したり便通を改善する方法が種々提案されている。例えば、ハトムギ（殻を剥いだものあるいは殻のついたもの）を粗粉砕したものにプロテアーゼとα−アミラーゼを加えて処理したものを粉末化して得られる、皮膚改善効果を有するハトムギエキス（特許文献１）、ハトムギ青葉の乾燥粉末または抽出物からなる、血中脂質量の抑制効果や血糖上昇抑制作用を有する抗酸化剤（特許文献２）、ハトムギ等の穀物に対し少なくとも２種の互いに基質特異性及び反応速度の異なる酵素（アミラーゼ、グルコシダーゼ、プロテアーゼ、及びペプチダーゼから選択される少なくとも２種の酵素）を反応させて得られる、メラニン産生抑制作用、表皮角化細胞増殖作用、あるいは保湿作用を有する穀物酵素分解物（特許文献３）、ハトムギの穀、薄皮、あるいは渋皮を発酵、又は酵素処理（ジアスターゼ剤、タカジアスターゼ剤、α−アミラーゼ剤、β−アミラーゼ剤、グルコアミラーゼ剤、ペクチナーゼ剤、β−グルコシダーゼ剤、セルラーゼ剤、ヘミセルラーゼ剤及びキシラナーゼ剤から選ばれる少なくとも一種）して得られるか、又はそれぞれをハトムギの子実の熱水抽出物、エタノール抽出物、発酵処理物及び酵素処理物のうち少なくとも一つからなる加工物に配合するか、又はそれぞれから抽出したオリゴ糖からなる腫瘍、ヒト乳頭腫ウィルス性疾患、皮膚改善、便秘の予防又は治療剤（特許文献４）、ハトムギに澱粉分解酵素（アミラーゼ）、蛋白質分解酵素（プロテアーゼ）、麹菌（米麹）、多糖類分解微生物の少なくとも一つを加えて反応させるか、この反応中または反応後に、酵母、乳酸菌、脂肪分解酵素の少なくとも一つをさらに加えて反応させて得られる、皮膚疾患改善効果、細胞活性化効果、皮膚改善効果を示すハトムギエキス（特許文献５）、薬用植物にデンプン分解酵素（アミラーゼ）、蛋白質分解酵素（プロテアーゼ）、こおじ菌、多糖類分解微生物のうち少なくとも一つを加え反応させるか、この反応中または反応後に、酵母、乳酸菌、脂肪分解酵素の少なくとも一つをさらに加えて反応させて生薬エキスを抽出する生薬エキス抽出方法およびイボ取り効果、肌活性効果、利尿効果を有する該生薬エキス（特許文献６）、ヨクイニン末の溶液にヨウ素を混和してできた発色液に、酵素〔澱粉分解酵素（アミラーゼ）、蛋白質分解酵素（プロテアーゼ）の混合物のほか、さらに繊維素分解酵素（セルラーゼ）または脂肪分解酵素（リパーゼ）を混合したもの〕を作用させて退色させることを特徴とする皮膚防御、改善性物質の製造法（特許文献７）、ハトムギ粉砕物を水に分散させ、これに耐熱性澱粉液化酵素（バシラス・サブチリス等の細菌アミラーゼ）を加えて撹拌処理する第一工程、糖化酵素（リゾプス系、アスペルギルス系）及び中性プロテアーゼ（アスペルギルス系、ストレプトミセス系、バシラス系プロテアーゼ、パパイン）を加え特定温度で処理後、ろ過、濃縮を行う第二工程とより成るハトムギ成分の抽出法（特許文献８）、などが知られている。
上記のハトムギを原料とし、酵素処理、発酵処理、抽出処理などを施して便通改善あるいは皮膚改善用物を得る従来法では、ハトムギの殻を剥いで得られるヨクイニンを原料として用いるものがほとんどであり（特許文献１、３、４、５、６、７、８）、また殻付きのハトムギ（特許文献１）を用いるものもあるが、ヨクイニンを原料として用いるもの共々、いずれも酵素分解処理後、遠心分離や濾過などにより不溶物または残渣を除去し、得られた上清や濾液を用いるものである。更に、ハトムギの青葉（特許文献２）を用いるものや、ハトムギの殻、薄皮、渋皮のみを用いるものもあるが（特許文献４）、これらは殻付きハトムギの粉砕物を用いるものではないし、ハトムギの青葉を用いるもの（特許文献２）では粉砕物、あるいは粉砕物を溶媒で抽出後、濾過を行い得られた濾液を用いるものである。
そして上記の従来法によるハトムギの酵素処理物では、その便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善効果や皮膚改善効果が満足のいくものでなく、また原料として一般的に用いられているヨクイニンを得るには殻をむく処理が必要であるなどの煩雑さがあった。
本発明者らは便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善効果や皮膚改善効果の優れたハトムギ酵素処理物を得るべく鋭意研究を進めた結果、原料として殻付きハトムギの粉砕物を用い、特定の酵素処理後、遠心分離や濾過などにより不溶物または残渣を除去することなく酵素処理物をそのまま乾燥させて得られたものが上記効果において優れていることを見出した。
本発明者らは更により効果の高い、ハトムギの酵素処理物を得るべく、ハトムギに作用させる酵素について検討を行った。これら酵素はハトムギに含まれる澱粉や蛋白質等を分解して摂取吸収されやすい形にするために用いられるのであるが、従来、糖加水分解酵素やプロテアーゼ、脂質分解酵素などが用いられている。その具体例を挙げると、アミラーゼ、グルコシダーゼ、プロテアーゼ、及びペプチダーゼから選択される少なくとも２種（特許文献３）、ジアスターゼ剤、タカジアスターゼ剤、α−アミラーゼ剤、β−アミラーゼ剤、グルコアミラーゼ剤、ペクチナーゼ剤、β−グルコシダーゼ剤、セルラーゼ剤、ヘミセルラーゼ剤及びキシラナーゼ剤から選ばれる少なくとも一種（特許文献４）、澱粉分解酵素（アミラーゼ）、蛋白質分解酵素（プロテアーゼ）の混合物のほか、さらに繊維素分解酵素（セルラーゼ）または脂肪分解酵素（リパーゼ）を混合したもの（特許文献７）、耐熱性澱粉液化酵素（バシラス・サブチリス等の細菌アミラーゼ）、糖化酵素（リゾプス系、アスペルギルス系）及び中性プロテアーゼ（アスペルギルス系、ストレプトミセス系、バシラス系プロテアーゼ、パパイン）（特許文献８）などである。本発明者らは便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善作用や皮膚改善作用の点でより効果の高い、ハトムギの酵素処理物を得るべく研究を重ねた結果、殻付きハトムギの粉砕物にα−アミラーゼ、プロテアーゼを作用させた後、更にこれまで用いられたことのないトランスグルコシダーゼを作用させて得られるハトムギの酵素分解物が、便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善作用や皮膚改善作用において非常に優れた効果を奏することを見出し、本発明に到達したものである。
Most of the conventional methods that use the above-mentioned pearl barley as a raw material and obtain an article for improving bowel movement or skin improvement by applying enzyme treatment, fermentation treatment, extraction treatment, etc., use yokoinin obtained by peeling pearl shells as the raw material. (
In addition, the above-mentioned conventional barley enzyme-treated products are not satisfactory in their bowel movements, low back pain, premenstrual syndrome (PMS), swelling, warts and skin improvement effects, and are generally used as raw materials. In order to obtain the yokoinin that has been used, the shelling process is necessary.
As a result of intensive research to obtain a pearlyme enzyme-treated product excellent in improving bowel movement, low back pain, premenstrual syndrome (PMS), swelling, warts and skin improvement effect, the present inventors crushed shelled pearl barley as a raw material. It was found that a product obtained by drying an enzyme-treated product as it is without removing insoluble matters or residues by centrifugation or filtration after the specific enzyme treatment using the product was excellent in the above effect.
The present inventors have examined an enzyme that acts on pearl barley in order to obtain a more highly effective processed product of pearl barley. These enzymes are used to decompose starch, proteins and the like contained in pearl barley into a form that is easily absorbed and absorbed. Conventionally, sugar hydrolases, proteases, lipolytic enzymes, and the like have been used. Specific examples thereof include at least two kinds selected from amylase, glucosidase, protease, and peptidase (Patent Document 3), diastase agent, takadiastase agent, α-amylase agent, β-amylase agent, glucoamylase agent, pectinase In addition to a mixture of at least one selected from an agent, β-glucosidase agent, cellulase agent, hemicellulase agent and xylanase agent (Patent Document 4), amylolytic enzyme (amylase), proteolytic enzyme (protease), and fibrinolytic enzyme (Cellulase) or a mixture of lipolytic enzyme (lipase) (Patent Document 7), heat-resistant starch liquefying enzyme (bacterial amylase such as Bacillus subtilis), saccharifying enzyme (Rhizopus, Aspergillus) and neutral protease (Aspergillus) Series, Streptomyces System, Bacillus based protease, papain) (Patent Document 8), and the like. As a result of repeated research to obtain an enzyme-treated product of pearl barley that is more effective in terms of bowel movements, low back pain, premenstrual syndrome (PMS), swelling, warts, and skin improvement, After allowing α-amylase and protease to act on pulverized pearl barley, and further causing transglucosidase, which has never been used before, to produce an enzyme degradation product of pearl barley, bowel movements, low back pain, premenstrual syndrome (PMS) It has been found that the present invention has achieved excellent effects in improving swelling and warts and improving skin.
本発明は
（１）殻付きハトムギの粉砕物をα−アミラーゼ、プロテアーゼで処理した後、更にトランスグルコシダーゼを作用させ、得られる処理物をそのまま乾燥、粉末化したことを特徴とする、ハトムギ酵素分解物、
（２）１のハトムギ酵素分解物を含有する、便通及び健康状態の改善並びに皮膚の改善剤及び組成物、
（３）健康状態の改善が腰痛、月経前症候群（ＰＭＳ）、むくみの改善である（２）記載の便通及び健康状態の改善並びに皮膚の改善剤及び組成物、
（４）皮膚の改善がニキビ、イボ、肌及び爪の状態の改善である（２）記載の便通及び健康状態の改善並びに皮膚の改善剤及び組成物、
に関するものである。
In the present invention, (1) crushed ground barley is treated with α-amylase and protease, then further treated with transglucosidase, and the resulting treated product is dried and powdered as it is. object,
(2) Fecal and health condition improving and skin improving agent and composition, comprising 1 pearl barley enzyme degradation product,
(3) The improvement of the bowel movement and health condition and the skin improving agent and composition according to (2), wherein the improvement of the health condition is lower back pain, premenstrual syndrome (PMS), and improvement of swelling.
(4) The improvement of the bowel movement and health condition and the skin improving agent and composition according to (2), wherein the improvement of the skin is an improvement of acne, warts, skin and nails
It is about.
本発明では、殻付きハトムギの粉砕物を用い、酵素分解処理後得られる分解処理物を遠心分離や濾過などにより不溶物または残渣を除去することなく、そのまま乾燥して粉末とすることにより摂取可能な食物繊維量が増え、また酵素分解に当って、α−アミラーゼ、プロテアーゼに加え、従来用いられたことのないトランスグルコシダーゼを更に用いて処理することにより、腸内環境を整えるイソマルトオリゴ糖などの糖が生成し、その結果、便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボ等において優れた改善効果を有し、また優れた皮膚改善効果を有するハトムギ酵素分解物が得られたものである。
本発明の便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善並びに皮膚改善用組成物は、殻付きハトムギの粉砕物、即ちハトムギの殻（総苞）、薄皮（内外頴）、糠（果皮）、胚芽、ヨクイニン（胚乳）などの全てを使用し、上記の特定の酵素分解処理により、従来ハトムギで利用されることの多いヨクイニン粉末の抽出物にはない便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善、及び皮膚改善効果が確認された。その他、ヨクイニンと比べ、皮膚改善効果により、爪の健康や化粧のり・もち、くすみ、すべすべ感、しっとり感、口元のハリ、ソバカス、ニキビなどの改善効果が得られ、胃の調子などの健康状態を改善する効果も確認された。爪の健康や化粧もち、くすみなどの皮膚改善効果や月経前症候群（ＰＭＳ）、腰痛、胃の調子などの健康状態の改善効果は抽出物を用いる従来技術（特許文献１、３、４、５、７）では認識されていなかった効果である。
また、本発明によりハトムギ全粒を美味しく、また食べやすくすることが可能となった。
更に本発明では殻付きハトムギの粉砕物を使用するので、殻を剥くなどの煩雑な処理が不要であり、その操作上の簡便さという効果をも有するものである。
In the present invention, a shelled barley pulverized product is used, and the digested product obtained after the enzymatic digestion treatment can be ingested by directly drying it into a powder without removing insoluble matters or residues by centrifugation or filtration. In addition to α-amylase and protease, in addition to α-amylase and protease, further treatment with transglucosidase, which has not been used in the past, isomaltoligosaccharide that adjusts the intestinal environment. Sugar was produced, and as a result, a pearl barley enzyme degradation product having an excellent improvement effect in bowel movements, low back pain, premenstrual syndrome (PMS), swelling, warts, etc., and an excellent skin improvement effect was obtained. is there.
The compositions for improving bowel movements, low back pain, premenstrual syndrome (PMS), swelling, warts and skin improvement of the present invention are crushed shelled barley, that is, barley shell (total cocoon), thin skin (inner and outer folds), wrinkles (Pericarp), germ, yokoinin (endosperm), etc., and by the above-mentioned specific enzymatic degradation treatment, bowel movements, low back pain, premenstrual syndrome not found in the extract of yokuinin powder that is often used in pearl barley in the past (PMS), swelling, wart improvement, and skin improvement effect were confirmed. In addition, compared with Yokuinin, skin improvement effects can improve nail health, makeup, moisturizing, dullness, smoothness, moistness, firmness of mouth, buckwheat, acne, and other health conditions such as stomach tone It was also confirmed that the effect was improved. Conventional techniques using extracts (
Further, the present invention makes it possible to make the whole grain of barley delicious and easy to eat.
Furthermore, in the present invention, a crushed product of shelled pearl barley is used, so that complicated processing such as peeling off the shell is unnecessary, and there is also an effect of simplicity in operation.
本発明のハトムギ酵素分解物の製造工程は次の表１に示す通りである。
本発明で用いられる殻付きハトムギは５ｍｍ以下に粗粉砕する。
過熱水蒸気による殺菌処理は１４１℃〜１５６℃で３秒程度行う。
殺菌処理後、気流式粉砕機にて４０メッシュＰａｓｓ、目開き４４５μｍ以下に微粉砕する。
該微粉砕物を９〜１０倍の割合の水に分散させ、７０℃〜８０℃程度まで加熱する。ここに水酸化ナトリウム水溶液などのアルカリ水溶液を添加し、温度７５℃以上で３時間程度反応、澱粉をα化させる。
このような処理をした後、α−アミラーゼ、プロテアーゼ、トランスグルコシダーゼを添加して酵素分解を行う。酵素分解は４０〜６０℃、ｐＨ４．０〜８．０程度で行う。
上記の酵素処理は通常、α−アミラーゼ、プロテアーゼ、トランスグルコシダーゼの順に作用させるが、α−アミラーゼ、プロテアーゼは同時に作用させることもできる。
The shelled pearl barley used in the present invention is roughly pulverized to 5 mm or less.
Sterilization with superheated steam is performed at 141 ° C. to 156 ° C. for about 3 seconds.
After the sterilization treatment, it is finely pulverized to 40 mesh Pass and an opening of 445 μm or less with an airflow pulverizer.
The finely pulverized product is dispersed in water at a ratio of 9 to 10 times and heated to about 70 ° C to 80 ° C. An aqueous alkali solution such as an aqueous sodium hydroxide solution is added thereto, and the reaction is carried out at a temperature of 75 ° C. or higher for about 3 hours to make the starch alpha.
After such treatment, α-amylase, protease, and transglucosidase are added to perform enzymatic degradation. Enzymatic degradation is carried out at 40-60 ° C. and pH 4.0-8.0.
The above-mentioned enzyme treatment is usually caused to act in the order of α-amylase, protease, and transglucosidase, but α-amylase and protease can be allowed to act simultaneously.
α−アミラーゼは、デンプンのα−１,４−グルコシド結合に作用して加水分解するエンド型の酵素であり、タカアミラーゼ、グリコゲナーゼとも呼ばれる。これらを該微粉砕物に対して、０．２％〜０．４％の割合で添加し、処理温度３５〜５５℃、ｐＨ４．０〜６．０、好ましくは４５〜５０℃、ｐＨ５．０〜５．５程度で、１〜６時間程度反応させる。 α-Amylase is an endo-type enzyme that acts on the α-1,4-glucoside bond of starch and hydrolyzes it, and is also called takaamylase or glycogenase. These are added to the finely pulverized product in a proportion of 0.2% to 0.4%, and the treatment temperature is 35 to 55 ° C., pH 4.0 to 6.0, preferably 45 to 50 ° C., pH 5.0. The reaction is performed at about 5.5 to about 1 to 6 hours.
プロテアーゼとしては、セリンプロテイナーゼ、システインプロテイナーゼ、金属プロテイナーゼ、アスパルティックプロテイナーゼ、アミノペプチダーゼ、カルボキシペプチダーゼなどの混合物が用いられる。
これらを、該微粉砕物に対して、０．１％〜０．３％の割合で添加し、処理温度４０〜６０℃、ｐＨ５．０〜８．０、好ましくは４５〜５０℃、ｐＨ６．０〜７．０程度で、１〜４時間程度反応させる。
As the protease, a mixture of serine proteinase, cysteine proteinase, metal proteinase, aspartic proteinase, aminopeptidase, carboxypeptidase and the like is used.
These are added to the finely pulverized product at a ratio of 0.1% to 0.3%, and the treatment temperature is 40 to 60 ° C., pH 5.0 to 8.0, preferably 45 to 50 ° C., pH 6. The reaction is performed at about 0 to 7.0 for about 1 to 4 hours.
トランスグルコシダーゼはα−グルコシダーゼ、マルターゼなどの別名をもち、基質の非還元末端からα−グルコースを加水分解により遊離するエキソ型の酵素であるが、加水分解反応と同時に糖転移反応もしばしば触媒することから、トランスグルコシダーゼとも呼ばれてきた。転移生成物から、トランスグルコシダーゼ（α−グルコシダーゼ）はα−１,６−グルコシル転移型、α−１,４−グルコシル転移型、およびα−１,２−ならびにα−１,３−グルコシル転移型等に分類でき、α−１,６−グルコシル転移型α−グルコシダーゼがイソマルトオリゴ糖、α−１,２−ならびにα−１,３−グルコシル転移型α−グルコシダーゼがコージビオースあるいはニゲロースなどの製造に用いられている。いずれのα−グルコシダーゼも用いることができるが、本発明ではイソマルトオリゴ糖を生成するα−１,６−グルコシル転移型α−グルコシダーゼを用いるのが特に好ましい。イソマルトオリゴ糖は、イソマルトース、パノース、イソマルトトリオースなどのα−１,６結合を分子内に少なくとも１つ以上有する重合度２〜６分岐オリゴ糖である。
トランスグルコシダーゼを、該微粉砕物に対して、０．１％〜０．３％の割合で添加し、処理温度４５〜６０℃、ｐＨ４．０〜７．０、好ましくは５５〜６０℃、ｐＨ５．０〜６．０の程度で、１〜３時間程度反応させる。
Transglucosidase is an exo-type enzyme that has other names such as α-glucosidase and maltase and liberates α-glucose from the non-reducing end of the substrate by hydrolysis, but it often catalyzes the transglycosylation reaction simultaneously with the hydrolysis reaction. Therefore, it has also been called transglucosidase. From the transfer product, transglucosidase (α-glucosidase) is α-1,6-glucosyl transfer type, α-1,4-glucosyl transfer type, and α-1,2- and α-1,3-glucosyl transfer type. Α-1,6-glucosyl transfer type α-glucosidase is used for the production of isomaltoligosaccharide, α-1,2- and α-1,3-glucosyl transfer type α-glucosidase is used for the production of cordobiose or nigerose, etc. It has been. Any α-glucosidase can be used, but in the present invention, it is particularly preferable to use α-1,6-glucosyl transfer type α-glucosidase which generates isomaltoligosaccharide. The isomaltoligosaccharide is a 2-6 branched oligosaccharide having at least one α-1,6 bond in the molecule, such as isomaltose, panose, isomaltotriose.
Transglucosidase is added to the finely pulverized product at a ratio of 0.1% to 0.3%, and the treatment temperature is 45 to 60 ° C., pH 4.0 to 7.0, preferably 55 to 60 ° C.,
本発明のハトムギ酵素分解物は便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善並びに皮膚改善剤として有効であり、又、皮膚改善効果により、爪の健康や化粧のり・もち、くすみ、すべすべ感、しっとり感、口元のハリ、ソバカス、ニキビなどの改善効果が得られ、胃の調子などの健康状態を改善する効果もあり、ハトムギ酵素分解物を主成分として含有する便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善並びに皮膚改善又、皮膚改善効果による爪の健康や化粧のり・もち、くすみ、すべすべ感、しっとり感、口元のハリ、ソバカス、ニキビなどの改善、胃の調子などの健康状態の改善用組成物或いは食品として利用される。 The pearl barley enzyme degradation product of the present invention is effective as an agent for improving bowel movements, low back pain, premenstrual syndrome (PMS), swelling, warts, and a skin improving agent. Also, due to the skin improving effect, nail health, makeup paste / mochi, dullness , Smooth feeling, moist feeling, improved elasticity such as firmness of the mouth, buckwheat, acne, etc., there is also an effect to improve the health condition such as stomach condition, bowel movement containing pearl barley enzyme degradation product as a main component, low back pain, Improvement of premenstrual syndrome (PMS), swelling, warts, skin improvement, and nail health, makeup, moisturizing, dullness, smoothness, moist feeling, firmness of mouth, buckwheat, acne, stomach It is used as a composition for improving the health condition such as the condition of food or food.
本発明のハトムギ酵素分解物を主成分として含有する便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善並びに皮膚改善又、皮膚改善効果による爪の健康や化粧のり・もち、くすみ、すべすべ感、しっとり感、口元のハリ、ソバカス、ニキビなどの改善、胃の調子などの健康状態の改善用組成物の形態は特に限定されないが、例えば、散剤、粉末剤、顆粒剤、細粒剤、錠剤、丸剤、カプセル剤、シロップ剤、ドリンク剤などいずれの形態でもよく、ハトムギ酵素分解物を３０から１００重量％含有し、その他、通常用いられる賦形剤、これを更に分類すると、錠剤にする際に粉末をまとめるための還元麦芽水飴、無水結晶ぶどう糖、でんぷん、乳糖、ぶどう糖などの結着剤、二酸化珪素、乾燥ビール粉末などの吸湿性改善剤、ステアリン酸カルシウム、食用乳清カルシウム粉などの流動性改善剤、ワックス類などの滑沢剤、着色料、甘味料、香料など医薬製剤製造に通常用いられる生理学的に許容し得る添加剤を適宜、含有することができる。これら添加剤の量は特に制限されないが、５から７０重量％程度である。 Improvement of bowel movements, low back pain, premenstrual syndrome (PMS), swelling, warts and skin improvement and skin improvement, skin paste, mochi, mochi, dull, smooth The form of the composition for improving the health condition such as feeling, moist feeling, firmness of the mouth, buckwheat, acne, etc., stomach condition is not particularly limited, for example, powder, powder, granules, fine granules, Tablets, pills, capsules, syrups, drinks, etc. may be in any form, containing 30 to 100% by weight of pearl barley enzyme degradation products, and other commonly used excipients. Reduced malt starch syrup, anhydrous crystalline glucose, starch, lactose, glucose etc. binders, silicon dioxide, dry beer powder etc. Physiologically acceptable additives usually used in the manufacture of pharmaceutical preparations such as calcium phosphate, fluidity improvers such as edible whey calcium powder, lubricants such as waxes, colorants, sweeteners, fragrances, etc. Can be contained. The amount of these additives is not particularly limited, but is about 5 to 70% by weight.
以下に本発明を製造実施例、製造比較例、モニター試験により説明するが、本発明はこれらの例に限定されるものでないことは言うまでもない。 The present invention will be described below with reference to production examples, production comparative examples, and monitor tests, but it goes without saying that the present invention is not limited to these examples.
Ｉ．本発明ハトムギ酵素分解物と従来のヨクイニン末とにおける便通などの健康状態、肌の状態に対する改善効果の比較
〔実施例１〕（本発明ハトムギ酵素分解物の製造）
殻付きハトムギを粗粉砕した後、過熱水蒸気により殺菌（１５６℃、３秒間）、微粉砕（４０メッシュＰａｓｓ、目開き４４５μｍ）した。この粉砕物４００ｋｇに３６００Ｌの水を加え、７５℃まで加熱した。ここに２５％水酸化ナトリウム溶液を１８Ｌ添加し、温度７５℃以上で３時間反応させた。水溶液を５０〜５２℃に調整し、塩酸でｐＨを５．４５〜５．５５に調整後、α−アミラーゼ（スミチームＬ（登録商標）、新日本化学工業（株））を１．３ｋｇ添加、α−アミラーゼ添加から２時間後プロテアーゼ（スミチームＬＰ（登録商標）、新日本化学工業（株））を０．９ｋｇ、α−アミラーゼ添加から３時間後糖転移酵素（トランスグルコシダーゼＬ、天野エンザイム（株））を０．９Ｌ添加した。糖転移酵素添加から３時間後、水酸化ナトリウム溶液を加えｐＨを６．９〜７．１に調整、液温を７０℃以上に上昇させ３０分間保持し酵素を失活させた。この液体をＢｒｉｘ（糖度）が１９〜２２になるまで濃縮した。その後、液温を８０℃以上に上昇させ、１時間保持後、スプレードライで乾燥させ、ハトムギ酵素分解物を製造した。得られたハトムギ酵素分解物は、僅かに甘味を有する灰褐色、粉状であった。
I. Comparison of improvement effect on health condition and skin condition such as bowel movement between the present invention barley enzyme degradation product and conventional yokoinin powder [Example 1] (Production of the present barley enzyme degradation product)
After pulverizing the shelled pearl barley, it was sterilized with superheated steam (156 ° C., 3 seconds) and finely pulverized (40 mesh Pass, opening 445 μm). 3400 L of water was added to 400 kg of the pulverized product and heated to 75 ° C. 18 L of 25% sodium hydroxide solution was added thereto and reacted at a temperature of 75 ° C. or higher for 3 hours. After adjusting the aqueous solution to 50 to 52 ° C. and adjusting the pH to 5.45 to 5.55 with hydrochloric acid, 1.3 kg of α-amylase (Sumiteam L (registered trademark), Shinnippon Chemical Co., Ltd.) was added, 2 hours after addition of α-amylase 0.9 kg of protease (Sumiteam LP (registered trademark), Shin Nippon Chemical Industry Co., Ltd.), 3 hours after addition of α-amylase glycosyltransferase (transglucosidase L, Amano Enzyme, Inc.) 0.9 L) was added. Three hours after the addition of glycosyltransferase, a sodium hydroxide solution was added to adjust the pH to 6.9 to 7.1, and the liquid temperature was raised to 70 ° C. or higher and maintained for 30 minutes to deactivate the enzyme. This liquid was concentrated until Brix (sugar content) became 19-22. Thereafter, the liquid temperature was raised to 80 ° C. or higher, held for 1 hour, and then dried by spray drying to produce a pearl barley enzyme degradation product. The obtained pearl barley enzyme degradation product was grayish brown and powdery with a slight sweetness.
〔実施例２〕（本発明ハトムギ酵素分解物含有組成物の製造）
実施例１で製造したハトムギ酵素分解物を用い、以下の表２に示す配合で原料を混合し、造粒、打錠を経て実施例１のハトムギ酵素分解物を含有するタブレットを得た。本タブレットは３００ｍｇ／粒であり４粒（１．２ｇ）を食することでハトムギ酵素分解物を１０００ｍｇ摂取することができる。本タブレット中の実施例１のハトムギ酵素分解物の配合割合は８３．３４重量％であった。
[Example 2] (Production of the present invention pearl barley enzyme degradation product-containing composition)
Using the barley enzyme degradation product produced in Example 1, the raw materials were mixed in the formulation shown in Table 2 below, and a tablet containing the barley enzyme degradation product of Example 1 was obtained through granulation and tableting. This tablet is 300 mg / grain and can eat 1000 mg of pearl barley enzyme digest by eating 4 grains (1.2 g). The blending ratio of the pearl barley enzyme degradation product of Example 1 in this tablet was 83.34% by weight.
（比較例1）（ヨクイニン末組成物の製造）
原料による効果の比較として、ヨクイニン末（山本漢方製薬（株））を用い、以下の表２に示す配合で原料を混合し、造粒、打錠を経てヨクイニン末を含有するタブレットを得た。本タブレットは３００ｍｇ／粒であり４粒（１．２ｇ）を食することでヨクイニン末を１０００ｍｇ摂取することができる。本タブレット中のヨクイニン末の配合割合は８３．３４重量％であった。
(Comparative Example 1) (Production of Yokuinin Powder Composition)
As a comparison of the effects of the raw materials, Yokuinin powder (Yamamoto Kampo Pharmaceutical Co., Ltd.) was used, and the raw materials were mixed in the composition shown in Table 2 below, and tablets containing yokuinin powder were obtained through granulation and tableting. This tablet is 300 mg / grain and can eat 1000 mg of Yokuinin powder by eating 4 tablets (1.2 g). The blending ratio of Yokuinin powder in this tablet was 83.34% by weight.
なお、本発明において示されているモニター試験は全て次の方法によっておこなったものである。
〔試験方法〕
モニター試験開始時と終了時に、アンケートを行い各質問項目に対し回答してもらった。
先入観により試験結果に偏りが出ないよう、ダブルブラインドテストで行った。
(1)先入観による結果の差異が出ないよう、被験者は試験品の種類を知らない。
(2)試験者の挙動が被験者に影響を与えないよう、試験者は被験者の服用している試験品の種類を番号で管理。
〔結果解析方法〕
「服用前に状態の悪い人数」に対する「服用前後での状態の悪い人の人数の変化」を百分率で表したもの、即ち、「服用前の状態の悪い人数−服用後の状態の悪い人数」を「服用前に状態の悪い人数」で割って百分率で表したものを改善率として以下のように算出した。
計算式：（服用前の状態の悪い人数−服用後の状態の悪い人数）÷服用前の状態の悪い人数×１００
例えば、摂取前に「状態が悪い」と回答した被験者の人数が８名、摂取後に「状態が悪い」という人数が３名であった場合、
改善率は（８−３）÷８×１００＝６２．５％となる。
All the monitor tests shown in the present invention were conducted by the following method.
〔Test method〕
At the start and end of the monitor test, a questionnaire was conducted and each question item was answered.
The double blind test was performed so that the test results were not biased by preconceptions.
(1) The subject does not know the type of test product so that there is no difference in the results of preconceptions.
(2) The tester manages the type of the test item that the subject is taking with a number so that the tester's behavior does not affect the subject.
[Result analysis method]
"Change in number of people in poor condition before and after taking" as a percentage of "number of people in bad condition before taking", ie, "number of people in bad condition before taking-number of people in bad condition after taking" Was divided by “number of people in bad condition before taking” and expressed as a percentage, and the improvement rate was calculated as follows.
Formula: (number of people in bad condition before taking-number of people in bad condition after taking) / number of people in bad condition before taking
For example, if there were 8 subjects who answered “bad” before ingestion and 3 people were “bad” after ingestion,
The improvement rate is (8-3) ÷ 8 × 100 = 62.5%.
（モニター試験１）
実施例２及び比較例１で調製したタブレットをそれぞれ男女１００名に１日４粒（１．２ｇ）を４週間摂取してもらった。表３にモニター１日あたりの各成分の摂取量を示した。この表から分かるように、ハトムギ酵素分解物およびヨクイニン末の摂取量は１日あたり１０００ｍｇに相当する。
(Monitor test 1)
The tablets prepared in Example 2 and Comparative Example 1 were each taken by 100 men and women to take 4 tablets (1.2 g) per day for 4 weeks. Table 3 shows the intake amount of each component per monitor day. As can be seen from this table, the intake of pearl barley enzyme degradation product and yokoinin powder corresponds to 1000 mg per day.
摂取前と後に、各種項目に対し、自身の悩み具合を記入してもらった。各種項目について、摂取前に「状態が悪い」と回答した被験者の人数を母集団とし、摂取前の「状態が悪い」という人数から摂取後の「状態が悪い」という人数を引いた差の値から前記のように改善率を算出した結果を図１、２に示した。 Before and after the ingestion, I asked them to fill in their troubles about various items. For various items, the difference between the number of subjects who answered “bad” before ingestion and the number of “bad” after intake minus the number of “bad” after ingestion. 1 and 2 show the results of calculating the improvement rate as described above.
図１から分かるように、便通については本発明のハトムギ酵素分解物を含有する実施例２のものが４０％の改善率であり、便通が改善する効果が確認された。また、その質や時間なども改善する傾向が見られたのに対し、比較例１で調製したヨクイニン末含有のタブレットでは改善率-８％であり、便通が改善する効果は見られず、逆に便通が悪くなる、下痢をするなど、マイナスの効果を示しており、本発明のものが比較例に比し優れていることが分かる。
その他の健康状態に関しては、本発明のハトムギ酵素分解物を含有する実施例２のものではその改善率が、むくみにおいて２３％、胃の調子において２１％、生理前の症状において１９％、腰痛において１０％、肩こりにおいて７％、疲れにおいて５％、集中力で４％、汗のかき具合で０％であった。これに対して比較例１のヨクイニン末ではむくみにおいて１４％、胃の調子において１％、生理前の症状において７％、腰痛において−３％、肩こりにおいて７％、疲れにおいて３％、集中力で−１％、汗のかき具合で−１８％であった。このように、むくみ、胃の調子、生理前の症状、腰痛、疲れ、集中力の各項目で本発明のハトムギ酵素分解物を含有する実施例２のものが比較例１のヨクイニン末含有のものに比して優れた改善結果を示しており、肩こりについては実施例２と比較例１とで同等の効果が得られており、汗のかき具合では実施例２では特に変わらなかったのに対し、比較例１のものではマイナスの効果が示され、総合的に見て本発明のものが比較例に比し優れていることが分かる。
As can be seen from FIG. 1, the bowel movement of Example 2 containing the pearl barley enzyme degradation product of the present invention was improved by 40%, and the effect of improving bowel movement was confirmed. In addition, while the quality and time tended to improve, the tablet containing Yokuinin powder prepared in Comparative Example 1 had an improvement rate of -8%, and the effect of improving bowel movement was not seen. The results show negative effects such as poor bowel movement and diarrhea, and it can be seen that the present invention is superior to the comparative example.
With regard to other health conditions, the improvement rate was 23% for swelling, 21% for stomach condition, 19% for pre-physiological symptoms, and 19% for back pain. It was 10%, 7% for stiff shoulders, 5% for fatigue, 4% for concentration, and 0% for sweating. On the other hand, in Yokuinin powder of Comparative Example 1, 14% in swelling, 1% in stomach condition, 7% in pre-physiological symptoms, -3% in back pain, 7% in shoulder stiffness, 3% in fatigue, 3% in concentration -1% and -18% for sweating. Thus, in Example 2, containing the pearl barley enzyme degradation product of the present invention in each of the items of swelling, stomach condition, pre-physiological symptoms, low back pain, fatigue, and concentration, the one containing Yokuinin powder of Comparative Example 1 Compared to the above, the results of the improvement were shown. Regarding the stiff shoulder, the same effect was obtained in Example 2 and Comparative Example 1, and the degree of sweating was not particularly different in Example 2. The comparative example 1 shows a negative effect, and it can be seen that the invention of the present invention is superior to the comparative example as a whole.
図２から分かるように、肌の改善については、本発明のハトムギ酵素分解物を含有する実施例２のものではその改善率が、化粧のりで４８％、化粧もちで４６％、くすみで４０％、すべすべ感で３５％、しっとり感で３３％、口元のハリで２４％、イボで２４％、ニキビで２２％、全体的なハリで２１％、赤みで２０％、キメ状態で１９％、目の下のハリで１９％、ソバカスで１５％、しみで７％であった。これに対して比較例１のヨクイニン末では化粧のりで１６％、化粧もちで１８％、くすみで２０％、すべすべ感で２０％、しっとり感で２７％、口元のハリで１０％、イボで１０％、ニキビで２１％、全体的なハリで１９％、赤みで１７％、キメ状態で１４％、目の下のハリで１１％、ソバカスで８％、しみで８％であった。このように比較例１のヨクイニン末もある程度の改善率があるものの、本発明のものはどの項目においても優れた改善率を示し、特に化粧のり、化粧もち、くすみ、すべすべ感において比較例に比し大幅に改善効果が上がっていることが分かる。
このように本発明のハトムギ酵素分解物は比較例のヨクイニン末に比べて、便通をはじめとする健康状態の改善率及び肌の改善率の両者において優れていることが分かる。
As can be seen from FIG. 2, the improvement rate of the skin improvement of Example 2 containing the pearl barley enzyme degradation product of the present invention was 48% for makeup paste, 46% for makeup retention, and 40% for dullness. 35% for smoothness, 33% for moistness, 24% for firmness at the mouth, 24% for warts, 22% for acne, 21% for overall resilience, 20% for redness, 19% for textured, under
Thus, it can be seen that the pearl barley enzyme degradation product of the present invention is superior in both the improvement rate of the health condition including bowel movements and the improvement rate of the skin, compared with the Yokuinin powder of the comparative example.
II．本発明のハトムギ酵素分解物と比較例とにおける成分の違いについて
（比較例２）
本発明のハトムギ酵素分解物製造において、酵素としてα−アミラーゼ、プロテアーゼで処理した後、更にトランスグルコシダーゼを作用させること、および酵素処理後不溶物の除去を行わないことが特徴であることを明らかにするために、ハトムギ酵素分解において酵素としてα−アミラーゼ、プロテアーゼのみで処理し、トランスグルコシダーゼは作用させず、また酵素処理後、不溶物の除去を行った比較のための製品を次のようにして製造した。
殻付きハトムギを粉砕した後、過熱水蒸気により殺菌（１５６℃３秒間）、微粉砕（４０メッシュＰａｓｓ、目開き４４５μｍ）した。この粉砕物に９倍量の水を加え、７５℃まで加熱した。ここに２５％水酸化ナトリウム溶液を添加し、温度７５℃以上で３時間反応させた。水溶液を５０〜５２℃に調整し、塩酸でｐＨを５．４５〜５．５５に調整後、α−アミラーゼ（スミチームＬ（登録商標）、新日本化学工業（株））を添加、α−アミラーゼ添加から２時間後にプロテアーゼ（スミチームＬＰ（登録商標）、新日本化学工業（株））を加えた。α−アミラーゼ添加から６時間後、水酸化ナトリウム溶液を加え、ｐＨを６．９〜７．１に調整、液温を７０℃以上に上昇させ３０分間保持して酵素を失活させた。その後、不溶物をＮｏ．２のろ紙でろ過、除去し、得られた液体をフリーズドライで乾燥、粉末化したものを得た。この得られたものを、酵素としてトランスグルコシダーゼを働かせず、また酵素処理後不溶物を除去した比較製品として、ハトムギ酵素分解抽出物（比較例２）とした。
II. About the difference of the component in the pearl barley enzyme degradation product of this invention, and a comparative example (comparative example 2)
Clearly, in the production of the pearl barley enzyme degradation product of the present invention, after treatment with α-amylase or protease as an enzyme, transglucosidase is allowed to act further, and insoluble matter is not removed after the enzyme treatment. In order to do this, a product for comparison in which the treatment with only α-amylase and protease as an enzyme in the decomposition of pearl barley without the action of transglucosidase and the removal of insolubles after the enzyme treatment was performed as follows. Manufactured.
The shelled pearl barley was pulverized and then sterilized with superheated steam (156 ° C. for 3 seconds) and finely pulverized (40 mesh Pass, opening 445 μm). Nine times the amount of water was added to the pulverized product and heated to 75 ° C. A 25% sodium hydroxide solution was added thereto and reacted at a temperature of 75 ° C. or higher for 3 hours. The aqueous solution was adjusted to 50 to 52 ° C., adjusted to pH 5.45 to 5.55 with hydrochloric acid, α-amylase (Sumiteam L (registered trademark), Shinnippon Chemical Co., Ltd.) was added, α-amylase Two hours after the addition, protease (Sumiteam LP (registered trademark), Shin Nippon Chemical Industry Co., Ltd.) was added. Six hours after the addition of α-amylase, a sodium hydroxide solution was added to adjust the pH to 6.9 to 7.1, the liquid temperature was raised to 70 ° C. or higher, and the enzyme was inactivated by maintaining for 30 minutes. Thereafter, the insoluble matter was No. The resulting liquid was filtered and removed with No. 2 filter paper, and the obtained liquid was freeze-dried and powdered. The obtained product was used as a barley enzymatic degradation extract (Comparative Example 2) as a comparative product in which transglucosidase was not used as an enzyme and insoluble matter was removed after the enzyme treatment.
次の表４に本発明ハトムギ酵素分解物（実施例１）とヨクイニン末、及びトランスグルコシダーゼを働かせず不溶物を除去したハトムギ酵素分解抽出物（比較例２）の一般成分を比較して示す。
次の表５に本発明ハトムギ酵素分解物（実施例１）、トランスグルコシダーゼは作用させずに不溶物を除去したハトムギ酵素分解抽出物（比較例２）、ハトムギ全粒粉、ハトムギ殻およびヨクイニン末について、各々のケイ素含量を比較して示す。
Table 5 below shows the present invention barley enzyme degradation product (Example 1), the barley enzyme degradation extract (Comparative Example 2) from which insolubles were removed without the action of transglucosidase, barley whole grain flour, barley husk and yokoinin powder. Each silicon content is shown in comparison.
III．本発明ハトムギ酵素分解物と比較例２のハトムギ酵素分解抽出物および従来のヨクイニン末とにおける、健康状態、肌、ニキビ、爪の改善に対する効果の比較
〔実施例３〕
実施例１で製造したハトムギ酵素分解物を用い、ステアリン酸カルシウム、乾燥ビール粉末、食用乳清カルシウム粉を加えて混合し、造粒、充填を経て、実施例１のハトムギ酵素分解物を含有するハードカプセルを得た。このときの配合割合を表６に、１日あたりの摂取量を表７に示す。
III. Comparison of effects of improving the health condition, skin, acne and nails of the present invention barley enzyme degradation product, the barley enzyme degradation extract of Comparative Example 2 and the conventional yokoinin powder [Example 3]
Hard capsule containing the pearl barley enzyme degradation product of Example 1 after adding and mixing calcium stearate, dry beer powder, and edible whey calcium powder using the pearl barley enzyme degradation product produced in Example 1 Got. Table 6 shows the blending ratio at this time, and Table 7 shows the daily intake.
（比較例３）
ヨクイニン末（山本漢方製薬（株））を用い、ステアリン酸カルシウム、乾燥ビール粉末、食用乳清カルシウム粉を加えて混合し、造粒、充填を経て、ヨクイニン末を含有するハードカプセルを得た。このときの配合割合を表６に、１日あたりの摂取量を表７に示す。
(Comparative Example 3)
Using Yokuinin powder (Yamamoto Kampo Pharmaceutical Co., Ltd.), calcium stearate, dried beer powder, and edible whey calcium powder were added and mixed, and after granulation and filling, a hard capsule containing yokuinin powder was obtained. Table 6 shows the blending ratio at this time, and Table 7 shows the daily intake.
（比較例４）
比較例２で製造したトランスグルコシダーゼを働かせず不溶物を除去したハトムギ酵素分解抽出物を用い、ステアリン酸カルシウム、乾燥ビール粉末、食用乳清カルシウム粉を加えて混合し、造粒、充填を経て、比較例２のハトムギ酵素分解抽出物を含有するハードカプセルを得た。このときの配合割合を表６に、１日あたりの摂取量を表７に示す。
(Comparative Example 4)
Using the pearl barley enzyme-degraded extract from which insolubles were removed without using the transglucosidase produced in Comparative Example 2, calcium stearate, dried beer powder, and edible whey calcium powder were added and mixed, and after granulation and filling, comparison A hard capsule containing the pearl barley enzymatic degradation extract of Example 2 was obtained. Table 6 shows the blending ratio at this time, and Table 7 shows the intake amount per day.
（モニター試験２）
実施例３、比較例３、比較例４で調製したカプセルをそれぞれ男女３０名に１日５粒、４週間摂取してもらった。この場合のハトムギ酵素分解物、ヨクイニン末、及びトランスグルコシダーゼを働かせず不溶物を除去したハトムギ酵素分解抽出物の各摂取量は１日あたり１０００ｍｇに相当する。
摂取前と後に、健康状態、肌の状態、ニキビの状態（ニキビの数、ニキビの大きさ、ニキビ跡、ニキビ跡の大きさ、ニキビ跡の濃さ、ニキビ跡の表面、ニキビのできやすさ）及び爪の状態（割れやすさ、つや、色、表面の段差・凸凹、表面の縦スジ、爪の伸び、二枚爪、巻き爪、ささくれ）について記入してもらった結果を図３〜６に示す。
(Monitor test 2)
The capsules prepared in Example 3, Comparative Example 3 and Comparative Example 4 were each taken by 30 men and women, 5 capsules a day for 4 weeks. In this case, each intake of the pearl enzyme digestion product, yokoinin powder, and the pearl enzyme digestion extract from which insolubles have been removed without using transglucosidase corresponds to 1000 mg per day.
Health condition, skin condition, acne condition (number of acne, size of acne, acne scar, size of acne scar, density of acne scar, surface of acne scar, ease of acne before and after intake ) And nail condition (ease of breakage, gloss, color, surface step / concave, surface vertical stripe, nail elongation, double nail, wound nail, crush) Shown in
図３は健康状態の改善率に関するグラフである。この図から分かるように、むくみ、胃の調子、生理前の症状、腰痛、肩こり、疲れ、集中力、汗のかき具合の各項目で本発明のハトムギ酵素分解物を含有する実施例３のものが各５８．３％、３３．３％、２３．１％、２６．７％、２３．５％、１０．５％、５３．８％、２０．０％の改善率を示したのに対し、従来のヨクイニン末含有の比較例３のものでは、各１６．７％、−１０．０％、０％、−３０．０％、０％、０％、１６．７％、−５０．０％の改善率％を、また比較例４のハトムギ酵素分解抽出物含有のものでは各０％、−２０．０％、１４．３％、−７．７％、０％、０％、０％、３３．３％の改善率を示しており、総合的に見て、本発明のハトムギ酵素分解物が従来のヨクイニン末（比較例３）、比較例４のハトムギ酵素分解抽出物に比べて明らかに優れている。 FIG. 3 is a graph regarding the improvement rate of the health condition. As can be seen from this figure, those of Example 3 containing the pearl barley enzyme degradation product of the present invention in each of the items of swelling, stomach tone, pre-menstrual symptoms, low back pain, stiff shoulders, fatigue, concentration and sweating. Showed improvement rates of 58.3%, 33.3%, 23.1%, 26.7%, 23.5%, 10.5%, 53.8% and 20.0%, respectively. In the case of Comparative Example 3 containing the conventional yokoinin powder, 16.7%, -10.0%, 0%, -30.0%, 0%, 0%, 16.7%, -50.0, respectively. % Improvement rate%, and those containing the pearl barley enzymatic degradation extract of Comparative Example 4 were 0%, -20.0%, 14.3%, -7.7%, 0%, 0%, 0%, respectively. The improvement rate of 33.3% is shown in a comprehensive view, and when viewed comprehensively, the decomposition product of the pearl barley enzyme of the present invention is the conventional yokoinin powder (Comparative Example 3) and the pearl barley enzyme content of Comparative Example 4. It is clearly superior compared to the extract.
図４は肌の改善率に関するグラフである。この図から分かるように、本発明のハトムギ酵素分解物を含有する実施例３のものでは化粧のりは３７．５％、化粧もちは３６．４％、くすみは２０．０％、すべすべ感では４１．７％、しっとり感では５０．０％、口元のハリでは７．１％、イボでは２０．０％、ニキビでは４２．９％、全体的なハリでは２７．３％、赤みで１６．７％、キメ状態で２３．１％、目の下のハリで３１．３％、ソバカスで２０．０％、しみで１６．７％、の各改善効果が確認された。
これに対し、比較例３のヨクイニン末含有のものでは化粧のりは−１６．７％、化粧もちは０．０％、くすみは４２．９％、すべすべ感では−３３．３％、しっとり感では３３．３％、口元のハリでは２５．０％、イボでは−３３．３％、ニキビでは−４００％、全体的なハリでは０％、赤みで−５０．０％、キメ状態で２７．３％、目の下のハリで１６．７％、ソバカスで−１００％、しみで２７．３％と、くすみ、口元のハリ、キメ状態、しみで本発明のものと同等以上の改善率を示し、しっとり感、目の下のハリで本発明には劣るもののある程度の改善率を示すものの、全体的なハリでは改善率が見られず、化粧のり、すべすべ感、イボ、ニキビ、赤み、ソバカスでは悪化した結果が出ている。
また、比較例４のハトムギ酵素分解抽出物のものでは化粧のりは１０．０％、化粧もちは７．７％、くすみは３７．５％、すべすべ感では１４．３％、しっとり感では２０．０％、口元のハリでは１４．３％、イボでは０％、ニキビでは１４．３％、全体的なハリでは３３．３％、赤みで２０．０％、キメ状態で２３．１％、目の下のハリで２１．４％、ソバカスで３３．３％、しみで１４．３％と、口元のハリ、全体的なハリ、赤み、ソバカスで本発明のものと同等以上の改善率を示し、化粧のり、化粧もち、くすみ、すべすべ感、しっとり感、ニキビ、キメ状態、目の下のハリ、しみで本発明には劣るもののある程度の改善率を示すものの、イボでは改善率が見られないという結果が出ている。
上記の結果から、肌の改善については本発明のハトムギ酵素分解物が、比較例のヨクイニン末、ハトムギ酵素分解抽出物に比べて総合的に見て優れた効果を奏していることが分かる。
FIG. 4 is a graph relating to the skin improvement rate. As can be seen from this figure, in Example 3 containing the pearl barley enzyme degradation product of the present invention, the makeup paste is 37.5%, the makeup duration is 36.4%, the dullness is 20.0%, and the smooth feeling is 41. 7%, moist feeling 50.0%, mouth firmness 7.1%, warts 20.0%, acne 42.9%, overall firmness 27.3%, redness 16.7% %, 23.1% in the textured state, 31.3% in the elasticity under the eyes, 20.0% in the buckwheat, 16.7% in the stain, were confirmed.
On the other hand, the one containing Yokuinin powder of Comparative Example 3 has a makeup paste of -16.7%, a makeup stickiness of 0.0%, a dullness of 42.9%, a smooth feeling of -33.3%, and a moist feeling. 33.3%, 25.0% in the mouth, -33.3% in warts, -400% in acne, 0% in overall elasticity, -50.0% in redness, 27.3 in textured condition %, 16.7% at the bottom of the eye, -100% at buckwheat, 27.3% at the spot, dullness, firmness at the mouth, textured condition, and spot, showing an improvement rate equal to or higher than that of the present invention, moist Although it shows an improvement rate to some extent although it is inferior to the present invention in the feeling and elasticity under the eyes, the improvement rate is not seen in the overall elasticity, but the result deteriorated in makeup glue, smooth feeling, wart, acne, redness, buckwheat Out.
In the case of the pearl barley enzymatic degradation extract of Comparative Example 4, the makeup paste was 10.0%, the makeup paste was 7.7%, the dullness was 37.5%, the smooth feel was 14.3%, and the moist feel was 20. 0%, 14.3% in the mouth, 0% in warts, 14.3% in acne, 33.3% in overall elasticity, 20.0% in redness, 23.1% in textured condition, under the eyes 21.4% for the skin, 33.3% for the buckwheat, and 14.3% for the stain, showing an improvement rate equal to or higher than that of the present invention in the mouth, overall skin, redness and buckwheat. Glue, makeup, dullness, smoothness, moist feeling, acne, textured state, firmness under the eyes, stains show some improvement rate that is inferior to the present invention, but warts do not show improvement rate. ing.
From the above results, it can be seen that the pearl barley enzyme-decomposed product of the present invention has an overall effect of improving the skin as compared with the yokoinin powder and barley enzyme-decomposed extract of the comparative example.
図５はニキビの改善率に関するグラフである。この図から分かるように、本発明のハトムギ酵素分解物を含有する実施例３のものではニキビ表面の凹凸は６６．７％、ニキビ跡の濃さは５０．０％、炎症のある赤ニキビ７５．０％、炎症の無い白・黒ニキビでは７１．４％、生理前のニキビでは７１．４％、ストレスによるニキビでは５０％、睡眠不足によるニキビでは８７．５％、食事によるニキビでは７５％、季節の変わり目によるニキビでは８３．３％、背中のニキビで５０％、首周りのニキビで５０％、ニキビの出来易さで６２．５％と各項目で非常に高い改善効果が確認された。
これに対し、比較例３のヨクイニン末含有のものではニキビ表面の凹凸は−５０．０％、ニキビ跡の濃さは−５０．０％、炎症のある赤ニキビ−１５０％、炎症の無い白・黒ニキビでは−２８．６％、生理前のニキビでは０％、ストレスによるニキビでは−２００％、睡眠不足によるニキビでは−２８．６％、食事によるニキビでは−１００％、季節の変わり目によるニキビでは０％、背中のニキビで０％、首周りのニキビで０％、ニキビの出来易さで−２００％と、ほとんど改善効果が無いか、逆に悪化するものが多いという結果が出ている。
また、比較例４のハトムギ酵素分解抽出物のものではニキビ表面の凹凸は２０．０％、ニキビ跡の濃さは１６．７％、炎症のある赤ニキビ−２０．０％、炎症の無い白・黒ニキビでは−１００％、生理前のニキビでは−１５０％、ストレスによるニキビでは−１４．３％、睡眠不足によるニキビでは０％、食事によるニキビでは２０％、季節の変わり目によるニキビでは−５０％、背中のニキビで−１００％、首周りのニキビで−１００％、ニキビの出来易さで０％と、ニキビ表面の凹凸、ニキビ跡の濃さ、食事によるニキビで本発明のものよりは低いものの多少の改善効果が見られる以外は、ほとんど改善効果が無いか、逆に悪化するものが多いという結果が出ている。
上記の結果から、ニキビの改善については、本発明のハトムギ酵素分解物が、比較例のヨクイニン末、ハトムギ酵素分解抽出物に比べて非常に優れた効果を奏していることが分かる。
FIG. 5 is a graph regarding the acne improvement rate. As can be seen from this figure, in Example 3 containing the pearl barley enzyme degradation product of the present invention, the unevenness on the surface of acne is 66.7%, the density of acne marks is 50.0%, and red acne with
On the other hand, the unevenness on the surface of acne is -50.0%, the density of acne marks is -50.0%, the red acne with inflammation is 150%, and the white without inflammation. -Black acne-28.6%, pre-menstrual acne-0%, stress acne-200%, sleep-induced acne-28.6%, dietary acne-100%, acne due to seasonal change Then, 0%, 0% for acne on the back, 0% for acne around the neck, -200% for the ease of acne, almost no improvement effect, there are many results that worsen .
Further, in the extract of the pearl barley enzyme-degraded extract of Comparative Example 4, the surface roughness of the acne is 20.0%, the density of the acne scar is 16.7%, the red acne with inflammation is 20.0%, and the white without inflammation. --100% for black acne, -150% for pre-menstrual acne, -14.3% for acne due to stress, 0% for acne due to lack of sleep, 20% for acne due to meals, -50 for acne due to seasonal change -100% for acne on the back, -100% for acne around the neck, 0% for acne ease, acne surface irregularities, acne darkness, acne caused by meals There is a result that there is almost no improvement effect or there are many things that deteriorate on the contrary, except that some improvement effect is seen although it is low.
From the above results, it can be seen that for the improvement of acne, the pearl barley enzyme-decomposed product of the present invention has a very excellent effect as compared with the yokoinin powder and barley enzyme-decomposed extract of the comparative example.
図６は爪の改善率に関するグラフであり、本発明のハトムギ酵素分解物を含有する実施例３のものではその改善率が、割れやすさにおいて５７．１％、つやで４２．９％、変色で５０．０％、表面の段差で５０．０％、表面の縦スジで３７．５％、爪の伸びでは０％、二枚爪で５０．０％、巻き爪で０％、ささくれが２８．６％であった。
これに対し、従来のヨクイニン末含有の比較例３では、割れやすさが２０．０％、つやで４４．４％、変色で３３．３％、表面の段差で０％、表面の縦スジで２８．６％、爪の伸びでは３３．３％、二枚爪で−１００．０％、巻き爪で−１００．０％、ささくれが０％であり、爪の伸びで本発明の実施例３に比べて優れており、またつやで本発明のものと同等である以外は、本発明のものに比し劣っており、二枚爪及び巻き爪では大巾に悪化しているものであった。
また、比較例４のハトムギ酵素分解抽出物では、割れやすさが１４．３％、つやで３３．３％、変色で２０．０％、表面の段差で１２．５％、表面の縦スジで３０．０％、爪の伸びでは６６．７％、二枚爪で０％、巻き爪で０％、ささくれが２８．６％であり、爪の伸びで本発明の実施例３に比べて優れており、またささくれで本発明のものと同等である以外は、本発明のものに比し劣っており、二枚爪及び巻き爪では改善効果が認められなかった。
以上のように、爪の改善率については総合的に見て、本発明のハトムギ酵素分解物が比較例のヨクイニン末やハトムギ酵素分解抽出物に比べてかなりの効果があることが分かる。
FIG. 6 is a graph relating to the improvement rate of the nail. In Example 3 containing the pearl barley enzyme degradation product of the present invention, the improvement rate is 57.1% in terms of ease of cracking, 42.9% in gloss, and discoloration. 50.0%, surface step 50.0%, surface vertical stripes 37.5%,
On the other hand, in Comparative Example 3 containing the conventional Yokuinin powder, the fragility is 20.0%, the gloss is 44.4%, the discoloration is 33.3%, the surface step is 0%, the surface vertical stripes 28.6%, nail elongation 33.3%, double nail -100.0%, wound nail -100.0%,
Moreover, in the pearl barley enzymatic degradation extract of Comparative Example 4, the fragility is 14.3%, the gloss is 33.3%, the discoloration is 20.0%, the surface level difference is 12.5%, and the surface vertical stripe is 30.0%, nail elongation is 66.7%, double nail is 0%, wound nail is 0%, and nail elongation is 28.6%, which is superior to Example 3 of the present invention in nail elongation. In addition, it was inferior to that of the present invention except that it was the same as that of the present invention, and no improvement effect was observed with the two nails and the wound nails.
As described above, it can be seen that the improvement rate of the nail is comprehensively seen from the pearl barley enzyme-degraded product of the present invention compared to the yokoinin powder and barley enzyme-decomposed extract of the comparative example.
IV．本発明ハトムギ酵素分解物と比較例２のハトムギ酵素分解抽出物および従来のヨクイニン末との便通の改善に対する効果の比較
〔実施例４〕（本発明ハトムギ酵素分解物含有組成物の製造）
実施例１で製造したハトムギ酵素分解物を用い、以下の表８に示す配合で原料を混合し、造粒、打錠を経て実施例１のハトムギ酵素分解物を含有するタブレットを得た。本タブレットは約３００ｍｇ／粒であり４粒（１．２ｇ）を食することでハトムギ酵素分解物を１０００ｍｇ摂取することができる。本タブレット中の実施例１のハトムギ酵素分解物の配合割合は８３．３４重量％であった。
IV. Comparison of effect on improvement of bowel movement between pearl barley enzyme degradation product of the present invention, pearl barley enzyme degradation extract of Comparative Example 2 and conventional Yokuinin powder [Example 4] (Production of pearl barley enzyme degradation product-containing composition of the present invention)
Using the barley enzyme degradation product produced in Example 1, the raw materials were mixed in the formulation shown in Table 8 below, and a tablet containing the barley enzyme degradation product of Example 1 was obtained through granulation and tableting. This tablet is about 300 mg / grain, and can eat 1000 mg of pearl barley enzyme degradation product by eating 4 grains (1.2 g). The blending ratio of the pearl barley enzyme degradation product of Example 1 in this tablet was 83.34% by weight.
（比較例５）（ヨクイニン末組成物）
ヨクイニン末（山本漢方製薬（株））を用い、以下の表８に示す配合で原料を混合し、造粒、打錠を経てヨクイニン末を含有するタブレットを得た。本タブレットは約３００ｍｇ／粒であり８粒（２．４ｇ）を食することでヨクイニン末を１０００ｍｇ摂取することができる。本タブレット中のヨクイニン末の配合割合は４１．６７重量％であった。
(Comparative Example 5) (Yokuinin powder composition)
Using Yokuinin powder (Yamamoto Kampo Pharmaceutical Co., Ltd.), the raw materials were mixed in the composition shown in Table 8 below, and after granulation and tableting, a tablet containing Yokuinin powder was obtained. This tablet is about 300 mg / grain and can eat 1000 mg of Yokuinin powder by eating 8 tablets (2.4 g). The blending ratio of Yokuinin powder in this tablet was 41.67% by weight.
（比較例６）
比較例２で製造したトランスグルコシダーゼを働かせず不溶物を除去したハトムギ酵素分解抽出物を用い、以下の表８に示す配合で原料を混合し、造粒、打錠を経てハトムギ酵素分解抽出物を含有するタブレットを得た。本タブレットは約２９０ｍｇ／粒であり８粒（２．３ｇ）を食することでハトムギ酵素分解抽出物を１０００ｍｇ摂取することができる。本タブレット中のハトムギ酵素分解抽出物の配合割合は４３．７５重量％であった。
Using the barley enzyme-degraded extract from which insolubles were removed without using the transglucosidase produced in Comparative Example 2, the raw materials were mixed in the composition shown in Table 8 below, and after passing through granulation and tableting, A containing tablet was obtained. This tablet is about 290 mg / grain, and can eat 1000 mg of pearl barley enzymatic degradation extract by eating 8 grains (2.3 g). The blending ratio of the pearl barley enzymatic degradation extract in this tablet was 43.75% by weight.
（モニター試験３）
実施例４、比較例５、比較例６で調製したタブレットをそれぞれ男女３０名に１日４粒（１．２ｇ）、８粒（２．４ｇ）、８粒（２．３ｇ）を４週間摂取してもらった。表９にモニター１日あたりの各成分の摂取量を示した。この表から分かるように、この場合のハトムギ酵素分解物、ヨクイニン末、及びトランスグルコシダーゼを働かせず不溶物を除去したハトムギ酵素分解抽出物の各摂取量は１日あたり１０００ｍｇに相当する。
Tablets prepared in Example 4, Comparative Example 5 and Comparative Example 6 were each taken by 30 men and women for 4 weeks (1.2 g), 8 (2.4 g) and 8 (2.3 g) for 4 weeks. I was asked to. Table 9 shows the intake amount of each component per monitor day. As can be seen from this table, each intake of pearl barley enzyme-degraded product, yokoinin powder, and pearl barley enzyme-degraded extract from which insolubles have been removed without using transglucosidase corresponds to 1000 mg per day.
摂取前と後に、便通の状態（１日の排便回数、排便時間の規則性、便の形、便の量、便の匂い、腸の動き、全体的な評価）について記入してもらった結果を図７に示す。
便の好ましい状態としては、次の基準で判定した。
形：水状＜泥状＜硬い固形＜バナナ状
量：なし〜少量＜バナナ1/2本＜バナナ1本＜バナナ2本
匂い：かなりある＜ややある＜あまりない＜ない
※好ましくない状態＜好ましい状態
腸の動きの確認方法は、各人の体感で回答を得た。
総合評価は、体感として、便通が服用前に比べて良くなったのかどうかの回答を得た。
Before and after ingestion, enter the results of the bowel movements (number of bowel movements per day, regularity of bowel movements, stool shape, stool volume, stool smell, bowel movements, overall evaluation) As shown in FIG.
The preferable state of stool was determined according to the following criteria.
Shape: Water <Muddy <Hard solid <Banana Amount: None ~ Small <1/2 Banana <1 Banana <2 Banana Odor: Pretty <Some <Some <Not <Not * Preferable <Preferable The method for confirming the state intestinal movement was answered by the experience of each person.
The overall evaluation gave an answer as to whether or not bowel movement was better than before taking.
図７は便通改善率に関するグラフであり、本発明のハトムギ酵素分解物を含有する実施例４のものではその改善率が、１日の排便回数において５０．０％、排便時間の規則性で７５．０％、便の形で３３．３％、便の量で２０．０％、便の匂いで２３．１％、腸の動きで６０．０％、全体的な評価で７４．１％であった。
これに対し従来のヨクイニン末含有の比較例５では、１日の排便回数において２０．０％、排便時間の規則性で２８．６％、便の形で２０．６％、便の量で１１．８％、便の匂いで−２８．６％、腸の動きで３３．８％、全体的な評価で−３３．３％であり、いずれの項目においても本発明のものに比べ劣っており、便の匂い及び全体的な評価は逆に悪化しているものであった。
また、比較例６のハトムギ酵素分解抽出物では、１日の排便回数において２９．４％、排便時間の規則性で７．４％、便の形で０％、便の量で０％、便の匂いで２０．６％、腸の動きで２５．０％、全体的な評価で−６６．７％であり、いずれの項目においても本発明のものに比べ劣っており、便の形、便の量では改善効果が無く、全体的な評価は逆に悪化しているものであった。
以上のように、便通の改善率については総合的に見て、本発明のハトムギ酵素分解物が比較例のヨクイニン末やハトムギ酵素分解抽出物に比べて非常に効果があることが図７から分かる。
FIG. 7 is a graph relating to the bowel movement improvement rate. In Example 4 containing the pearl barley enzyme degradation product of the present invention, the improvement rate is 50.0% in the number of defecations per day, and the regularity of the defecation time is 75. 0.0%, stool form 33.3%, stool volume 20.0%, stool odor 23.1%, bowel movement 60.0%, overall rating 74.1% there were.
On the other hand, in Comparative Example 5 containing the conventional yokoinin powder, 20.0% in the number of defecations per day, 28.6% in the regularity of the defecation time, 20.6% in the form of stool, 11 in the amount of stool .8%, stool odor -28.6%, bowel movement 33.8%, overall evaluation -33.3%, which is inferior to that of the present invention in all items On the contrary, the stool odor and the overall evaluation were worse.
In addition, the pearl barley enzymatic degradation extract of Comparative Example 6 was 29.4% in the number of defecations per day, 7.4% in the regularity of defecation time, 0% in the form of feces, 0% in the amount of feces, feces The odor of 20.6%, the intestinal movement was 25.0%, and the overall evaluation was -66.7%, which were inferior to those of the present invention in all items. There was no improvement effect with the amount, and the overall evaluation was worse.
As described above, it can be seen from FIG. 7 that the improvement rate of bowel movement is comprehensively seen from the pearl barley enzyme degradation product of the present invention compared to the yokoinin powder and barley enzyme degradation extract of the comparative example. .
本発明の便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善並びに皮膚改善用組成物は、優れた便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボの改善効果の他、皮膚改善効果により爪の健康や化粧のり・もち、くすみ、すべすべ感、しっとり感、口元のハリ、イボ、ソバカス、ニキビなど肌の状態や、胃の調子などの症状を改善する効果があり、爪の健康や化粧もち、くすみ、胃の調子、月経前症候群（ＰＭＳ）、腰痛の改善効果は従来技術にはない優れたものであり、美味しく、食べやすく、製造に当って殻を剥くなどの煩雑な処理が不要で簡便に得ることができ、便通、腰痛、月経前症候群（ＰＭＳ）、むくみ、イボ等の改善並びに皮膚改善用組成物として極めて有用なものである。 The composition for improving bowel movements, low back pain, premenstrual syndrome (PMS), swelling, warts and skin improvement of the present invention has excellent fecal bowel, low back pain, premenstrual syndrome (PMS), swelling, warts, skin, The effect of improving nail health, makeup, moisturizing, dullness, smoothness, moistness, firmness of mouth, warts, buckwheat, acne, and other symptoms such as stomach tone Health, makeup, dullness, stomach tone, premenstrual syndrome (PMS), and low back pain are superior to those of the prior art. They are delicious, easy to eat, and complicated to peel off during manufacturing. The treatment is unnecessary and can be easily obtained, and is extremely useful as a composition for improving bowel movements, low back pain, premenstrual syndrome (PMS), swelling, warts, etc., and skin.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009162741A JP5302800B2 (en) | 2008-07-14 | 2009-07-09 | Composition for improving bowel movements and skin |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008182192 | 2008-07-14 | ||
| JP2008182192 | 2008-07-14 | ||
| JP2009162741A JP5302800B2 (en) | 2008-07-14 | 2009-07-09 | Composition for improving bowel movements and skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010043069A true JP2010043069A (en) | 2010-02-25 |
| JP5302800B2 JP5302800B2 (en) | 2013-10-02 |
Family
ID=42014757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009162741A Active JP5302800B2 (en) | 2008-07-14 | 2009-07-09 | Composition for improving bowel movements and skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5302800B2 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014090675A (en) * | 2012-10-31 | 2014-05-19 | Sunstar Inc | Adlay extract-containing liquid composition |
| CN103948766A (en) * | 2014-05-09 | 2014-07-30 | 赵晓宏 | Traditional Chinese medicine for treating irregular menstrual periods |
| CN104547396A (en) * | 2014-12-24 | 2015-04-29 | 周连才 | Traditional Chinese medicinal composition for treating delayed menstrual cycle |
| CN104547612A (en) * | 2014-12-30 | 2015-04-29 | 黎平白娘子药业科研开发有限公司 | Six-component soup for women |
| CN104958692A (en) * | 2015-06-10 | 2015-10-07 | 兰毅 | Medicinal composition for treating hyperprolactinaemic infertility, and application thereof |
| CN105079373A (en) * | 2015-09-18 | 2015-11-25 | 顾梦婷 | Traditional Chinese medicine gynecological pad for treating female infertility |
| CN105168926A (en) * | 2015-09-17 | 2015-12-23 | 高冬梅 | Chinese herbal composite for treating hypomenorrhea after induced abortion operation |
| CN105214044A (en) * | 2015-10-16 | 2016-01-06 | 张绍阳 | A kind of Chinese medicine composition for nursing one's health female body health |
| CN105362687A (en) * | 2015-11-30 | 2016-03-02 | 济南邦文医药科技有限公司 | Traditional Chinese medicine composition for treating kidney deficiency and blood stasis type hypomenorrhea caused by postoperation intrauterine adhesion resulted from intrauterine adhesion operation |
| JP2016214198A (en) * | 2015-05-26 | 2016-12-22 | 株式会社ファイン | Health food using adlay and method for producing the same |
| JP2019089734A (en) * | 2017-11-15 | 2019-06-13 | 株式会社コーセー | Skin quality improvement agent |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS521042A (en) * | 1975-06-24 | 1977-01-06 | Koichi Ogawa | Toilet good |
| JP2003014739A (en) * | 2001-07-03 | 2003-01-15 | Shiseido Co Ltd | Screening method of skin swell improvement agent, and skin swell improvement agent |
| JP2005170830A (en) * | 2003-12-10 | 2005-06-30 | Asahi Soft Drinks Co Ltd | Melanogenesis inhibiting composition |
| JP2005298450A (en) * | 2004-04-15 | 2005-10-27 | Taisho Pharmaceut Co Ltd | Prophylactic or therapeutic agent composition for menopausal syndrome |
| JP2006519612A (en) * | 2003-03-10 | 2006-08-31 | ジェネンコー・インターナショナル・インク | Grain composition containing prebiotic isomaltoligosaccharide, method for producing the same, and use thereof |
| JP2006296255A (en) * | 2005-04-19 | 2006-11-02 | Maruzen Pharmaceut Co Ltd | Enzymatic decomposition product of cereal, method for producing the same and functional article |
| JP2008048723A (en) * | 2006-07-24 | 2008-03-06 | Fine Co Ltd | Method for producing adlay extract, and adlay extract |
-
2009
- 2009-07-09 JP JP2009162741A patent/JP5302800B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS521042A (en) * | 1975-06-24 | 1977-01-06 | Koichi Ogawa | Toilet good |
| JP2003014739A (en) * | 2001-07-03 | 2003-01-15 | Shiseido Co Ltd | Screening method of skin swell improvement agent, and skin swell improvement agent |
| JP2006519612A (en) * | 2003-03-10 | 2006-08-31 | ジェネンコー・インターナショナル・インク | Grain composition containing prebiotic isomaltoligosaccharide, method for producing the same, and use thereof |
| JP2005170830A (en) * | 2003-12-10 | 2005-06-30 | Asahi Soft Drinks Co Ltd | Melanogenesis inhibiting composition |
| JP2005298450A (en) * | 2004-04-15 | 2005-10-27 | Taisho Pharmaceut Co Ltd | Prophylactic or therapeutic agent composition for menopausal syndrome |
| JP2006296255A (en) * | 2005-04-19 | 2006-11-02 | Maruzen Pharmaceut Co Ltd | Enzymatic decomposition product of cereal, method for producing the same and functional article |
| JP2008048723A (en) * | 2006-07-24 | 2008-03-06 | Fine Co Ltd | Method for producing adlay extract, and adlay extract |
Non-Patent Citations (2)
| Title |
|---|
| JPN6012025346; 中医臨床 第２４巻，第３号, 2003, ｐ．３３７-３３９ * |
| JPN6013011114; 日本家政学会誌 第４４巻，第４号, 1993, ｐ．２４５-２５４ * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014090675A (en) * | 2012-10-31 | 2014-05-19 | Sunstar Inc | Adlay extract-containing liquid composition |
| CN103948766A (en) * | 2014-05-09 | 2014-07-30 | 赵晓宏 | Traditional Chinese medicine for treating irregular menstrual periods |
| CN104547396A (en) * | 2014-12-24 | 2015-04-29 | 周连才 | Traditional Chinese medicinal composition for treating delayed menstrual cycle |
| CN104547612A (en) * | 2014-12-30 | 2015-04-29 | 黎平白娘子药业科研开发有限公司 | Six-component soup for women |
| JP2016214198A (en) * | 2015-05-26 | 2016-12-22 | 株式会社ファイン | Health food using adlay and method for producing the same |
| CN104958692A (en) * | 2015-06-10 | 2015-10-07 | 兰毅 | Medicinal composition for treating hyperprolactinaemic infertility, and application thereof |
| CN105168926A (en) * | 2015-09-17 | 2015-12-23 | 高冬梅 | Chinese herbal composite for treating hypomenorrhea after induced abortion operation |
| CN105079373A (en) * | 2015-09-18 | 2015-11-25 | 顾梦婷 | Traditional Chinese medicine gynecological pad for treating female infertility |
| CN105214044A (en) * | 2015-10-16 | 2016-01-06 | 张绍阳 | A kind of Chinese medicine composition for nursing one's health female body health |
| CN105362687A (en) * | 2015-11-30 | 2016-03-02 | 济南邦文医药科技有限公司 | Traditional Chinese medicine composition for treating kidney deficiency and blood stasis type hypomenorrhea caused by postoperation intrauterine adhesion resulted from intrauterine adhesion operation |
| JP2019089734A (en) * | 2017-11-15 | 2019-06-13 | 株式会社コーセー | Skin quality improvement agent |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5302800B2 (en) | 2013-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5302800B2 (en) | Composition for improving bowel movements and skin | |
| KR101408568B1 (en) | Process of fermented food containing enzyme by using mixed Aspergillus oryzae and lactic acid bacteria | |
| CN109105736B (en) | Method for producing grain fermentation enzyme powder with increased fermentation efficiency using liquid seed culture fluid inoculated with Bacillus coagulans strain | |
| KR100988072B1 (en) | Fermented dendropanax morbifera lev. products and a pharmaceutical composition comprising the same | |
| JP6759337B2 (en) | A new strain derived from a traditional fermented food with excellent enzyme production ability and a method for producing a grain fermented enzyme food using the new strain. | |
| KR100894528B1 (en) | Skin care agent | |
| KR20180028736A (en) | Microbe Fermenting Agent for Improving Properties of Pill & Manufacturing Method of Pill for Absorption after Digestion Using the Same | |
| JPH0741426A (en) | Active oxygen scavenger from rice | |
| JP5695424B2 (en) | Substance for suppressing irritable bowel syndrome containing insoluble dietary fiber derived from cereal plant seeds | |
| JP5484913B2 (en) | Insoluble dietary fiber-containing substances derived from cereal plant seeds | |
| KR20090117363A (en) | Mixed culturing method of aspergillus oryzae and bacillus subtilis in rice bran, and it's processing methods | |
| JP2008048723A (en) | Method for producing adlay extract, and adlay extract | |
| JP2002281922A (en) | METHOD FOR PRODUCING FOOD MATERIAL WITH INCREASED gamma- AMINOBUTYRIC ACID CONTENT | |
| JP2011126833A (en) | Autonomic nerve regulator | |
| JP2022077034A (en) | Hibiscus hamabo extract, cosmetics containing the hibiscus hamabo extract and functional food | |
| TW202108122A (en) | External agent for hair restoration/hair growth | |
| JP5732274B2 (en) | Product obtained using moss and process for producing the same | |
| KR20210125218A (en) | Preparation method of bowel movement promotion functional fermentation product and bowel movement promotion functional fermentation product prepared by the same | |
| KR102476982B1 (en) | The composition for the weight control including the grains fermentation product and garcinia cambogia | |
| JP6158147B2 (en) | Whitening agent and internal or external composition containing the same | |
| JP2019089734A (en) | Skin quality improvement agent | |
| KR102438059B1 (en) | Composition for weight control containing garcinia cambogia extract and enzyme | |
| KR102441174B1 (en) | Manufacturing method of synbiotics comprising isomalto-oligosaccharide made from rice powder | |
| KR102338680B1 (en) | Method for manufacturing functional mugwort and brown rice cake | |
| KR102042448B1 (en) | Composition of Enzyme Food for Strengthening Scalp Hair and Manufacturing Method Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120605 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120720 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120725 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130508 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130618 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130621 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5302800 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |